Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M96,039Revenue (TTM) $M22,005Net Margin (%)11.1Altman Z-Score3.6
Enterprise Value $M102,986EPS (TTM) $2.3Operating Margin %16.3Piotroski F-Score6
P/E(ttm)37.8Beneish M-Score-2.8Pre-tax Margin (%)14.5Higher ROA y-yN
Price/Book6.810-y EBITDA Growth Rate %13.6Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %-8.3Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow24.4y-y EBITDA Growth Rate %6.1ROA % (ttm)6.4Higher Current Ratio y-yN
Dividend Yield %2.4PEG--ROE % (ttm)16.9Less Shares Outstanding y-yY
Payout Ratio %89.0Shares Outstanding M1,101ROIC % (ttm)11.2Gross Margin Increase y-yY

Gurus Latest Trades with LLY

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

LLY is held by these investors:



LLY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LILLY ENDOWMENT INC10% Owner 2017-10-04Sell205,000$86.810.51view
LILLY ENDOWMENT INC10% Owner 2017-09-29Sell195,000$85.142.48view
LILLY ENDOWMENT INC10% Owner 2017-09-15Sell190,000$82.535.72view
LILLY ENDOWMENT INC10% Owner 2017-08-31Sell180,000$81.067.64view
LILLY ENDOWMENT INC10% Owner 2017-07-31Sell220,000$83.095.01view
LILLY ENDOWMENT INC10% Owner 2017-06-22Sell210,000$84.433.34view
LILLY ENDOWMENT INC10% Owner 2017-06-20Sell215,000$83.055.06view
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM 2017-06-12Sell1,900$80.788.01view
Harrington Michael JSenior VP and General Counsel 2017-06-09Sell22,833$79.979.1view
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA 2017-05-04Sell25,000$82.765.43view

Press Releases about LLY :

Quarterly/Annual Reports about LLY:

News about LLY:

Articles On GuruFocus.com
Novo Nordisk Gets FDA Panel's OK for Diabetes Drug Oct 20 2017 
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines Oct 18 2017 
Lilly Declares Fourth-Quarter 2017 Dividend Oct 16 2017 
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® ( Oct 16 2017 
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Ini Oct 12 2017 
Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRA Oct 10 2017 
Thinking about buying stock in Disney, Johnson & Johnson, Eli Lilly, Mazor Robotics Ltd or Wells Far Oct 09 2017 
Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ Oct 06 2017 
U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent Oct 05 2017 
Additional Delivery of Insulin Ready for Distribution in Puerto Rico Oct 05 2017 

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK